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Abstract
Increased cardiovascular (CV) morbidity and mortality have been found in rheumatoid arthritis (RA). Tumour necrosis 
factor α (TNF-α) inhibitors may improve vascular function. In the first part of this study, we determined microcirculation 
during postoocclusive reactive hyperemia (PORH) representing endothelial function. In a nonselected population (n = 46) 
we measured flow-mediated vasodilation (FMD) of the brachial artery and laser Doppler flow (LDF) by ultrasound. Among 
LDF parameters, we determined TH1 (time to half before hyperemia), TH2 (time to half after hyperemia), Tmax (time to 
maximum) and total hyperemic area (AH). We measured von Willebrand antigen (vWF:Ag) by ELISA. In the second part 
of the study, we assessed the effects of adalimumab treatment on microcirculatory parameters in 8 early RA patients at 0, 
2, 4, 8 and 12 weeks. We found significant positive correlations between FMD and LDF Tmax (R = 0.456, p = 0.002), FMD 
and TH2 (R = 0.435, p = 0.004), and negative correlation between vWF:Ag and Tmax (R = − 0.4, p = 0.009) and between 
vWF:Ag and TH2 (R = − 0.446, p = 0.003). Upon adalimumab therapy in early RA, TH2 times improved in comparison 
to baseline  (TH2baseline = 26.9 s vs.  TH24weeks = 34.7 s, p = 0,032), and this effect prolonged until the end of treatment 
 (TH28weeks = 40.5, p = 0.026;  TH212weeks = 32.1, p = 0.013). After 8 weeks of treatment, significant improvement was found 
in AHa  (AHbaseline = 1599 Perfusion Units [PU] vs.  AH8weeks = 2724 PU, p = 0.045). The PORH test carried out with LDF 
is a sensitive option to measure endothelial dysfunction. TH1 and TH2 may be acceptable and reproducible markers. In our 
pilot study, treatment with adalimumab exerted favorable effects on disease activity, endothelial dysfunction and microcir-
culation in early RA patients.
Keywords Rheumatoid arthritis · Endothelial dysfunction · Atherosclerosis · Flow-mediated vasodilatation · Laser dopller 
flowmetry · Microcirculation · Adalimumab
Abbreviations
Ach  Acetylcholine
BMI  Body mass index
CRP  C-reactive protein
DAS28  28-Joint disease activity scale
DMARD  Disease-modifying antirheumatic drug
ED  Endothelial dysfunction
FMD  Flow-mediated vasodilation
GTN  Glyceryl trinitrate
LDF  Laser Doppler flowmetry
LSCI  Laser speckle contrast imaging
NO  Nitric oxide
PORH  Post-occlusive reactive hyperemia
RA  Rheumatoid arthritis
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SNP  Sodium nitroprusside
TNF-α  Tumour necrosis factor alpha,
vWF:Ag  Von Willebrand factor antigen
Introduction
Increased cardiovascular morbidity and mortality have 
been associated with rheumatoid arthritis (RA) and other 
inflammatory arthritides [1–8]. Both systemic inflamma-
tion and traditional cardiovascular risk factors are involved 
in this process [4, 8]. Endothelial dysfunction (ED) is con-
sidered to be the earliest sign of vascular pathophysiol-
ogy underlying atherosclerosis. Thus, it may be a promis-
ing tool to detect high cardiovascular risk early [9, 10]. 
Despite the 25 years of experience in the detection of ED, 
its clinical utility has not been clearly defined due mainly 
to technical pitfalls and high variability [10, 11].
The most attractive approach to the assessment of ED 
seems to be postocclusive reactive hyperemia (PORH), 
where dynamic changes of capillary flow and resistance, 
conduit vessel flow and/or diameter may be detected. The 
brachial artery flow mediated, endothelium-dependent 
dilation (FMD) is the prototype of noninvasive endothelial 
function tests [10–14]. Under standard conditions, FMD 
may be the method of choice for the noninvasive deter-
mination of macrovascular ED [2, 10, 14]. In contrast, 
the laser Doppler flowmetry (LDF) allows to record blood 
flow during the PORH test on the microvascular level [10, 
14]. In the case of LDF, most investigators applied acetyl-
choline (Ach) or sodium nitroprusside (SNP) iontophore-
sis during the assessment to detect endothelium-dependent 
and -independent microvascular function, respectively [10, 
14–16]. To date, there have been few studies using LDF 
in RA. Most studies included Ach and/or SNP iontopho-
resis and were carried out in established but not early RA 
[15–21]. Only Ruiz-Limon et al. [22] applied PORH and 
LDF. Most studies did not correlate micro- and macro-
vascular pathophysiology [15–17, 21, 23–26]. In general, 
impaired endothelium-dependent microcirculation was 
found in RA [15, 17, 18, 21, 22, 24–27]. Two studies 
involved early RA patients, but LDF results were not cor-
related with FMD [26, 28].
In this study, we wished to determine the relationship of 
brachial artery FMD to the measured and calculated LDF 
PORH parameters to validate the probably best microcir-
culatory measure of ED. Then, as there have been very few 
studies carried out in early, untreated RA, we conducted 
a longitudinal pilot study to verify the clinical utility of 
microcirculatory PORH in inflammatory arthritis.
Subjects and methods
Healthy subjects and patients
In the first cross-sectional part of the study, 46 consecu-
tive, unselected subjects were recruited from hospital prac-
titioners and inpatient relatives representing the general 
population. There were 28 females and 18 males, with 
a mean age of 38 years (range 21–70 years). Exclusion 
criteria included known cardio- and cerebrovascular dis-
eases, hypertension (blood pressure > 140/90 mmHg), 
diabetes mellitus, cigarette smoking, obesity (body mass 
index, BMI ≥ 30 kg/m2), current inflammatory, infectious 
disease or renal failure (serum creatinine ≥ 117 mmol/l). 
None of the patients received aspirin, clopidogrel, heparin 
or warfarin or vasoactive drugs.
In the second, pilot part of the study we longitudinally 
assessed the effects of the tumour necrosis factor α (TNF-
α) inhibitor adalimumab on microcirculatory (LDF), 
macrovascular (brachial artery FMD) function, as well as 
vWF:Ag levels (biomarker of endothelial activation) in 
patients with early, untreated RA. Eight early RA patients 
(6 females and 2 males) with a mean age of 37.8 years 
(range 24–66  years) were included in the study. All 
patients had a disease duration ≤ 1 year. The mean disease 
duration was 5.6 months (range 3–11 months). All early 
RA patients satisfied the 2010 EULAR/ACR classification 
criteria for RA [29]. We recruited these RA patients from 
a pool of > 700 patients continuously undergoing follow-
ups in our institution. None of the patients received corti-
costeroids, traditional or biologic disease-modifying anti-
rheumatic drugs (DMARD) prior to the study. All patients 
received 40 mg adalimumab sc biweekly and vascular 
examinations were performed at baseline and 2, 4, 8 and 
12 weeks after the initiation of treatment.
The study was approved by the Hungarian Scientific 
Research Council Ethical Committee (approval No. 
14,804–2/2011/EKU). Written informed consent was 
obtained from each patient and assessments were carried 
out according to the Declaration of Helsinki.
Assessment of microvascular and macrovascular 
function
All assessments were carried out under standard condi-
tions in an air-conditioned room at 21 °C after 20-min 
acclimatization, always in the morning. All subjects were 
fasting and had not used alcohol, tobacco, antioxidants and 
vasoactive drugs during the past 24 h according to current 
guidelines [30, 31].
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For LDF assessments, individuals were placed in supine 
position and the right arm was fixed. A pneumatic cuff 
was firmly placed around the lower arm just below the 
antecubital fossa and two, one-point LDF probes (Perif-
lux 4001 instrument, PF408, Perimed AB, Järfälla, Swe-
den) were applied to the forearm skin just below the cuff 
very close to each other proximally and distally aiming 
to record a primary and a control perfusion curves. Laser 
signal (780 nm wavelength) enters the upper layer of the 
skin and gets reflected from red blood cells in the circula-
tion. A frequency shift is detected and flux is expressed in 
perfusion units (PU) which may be continuously recorded. 
Among LDF PORH parameters, the most relevant ones 
were time to maximum (TM), time to half before (TH1) 
and after hyperemia (TH2), acceleration phase of laser 
Doppler curve (AUCaccel), total hyperemic area (AH), 
its decelerating (AUC decel) and one-minute long segment 
(AUC 1min), peak flux (PF) (Table 1).
To detect FMD, a B-mode longitudinal section was 
obtained of the brachial artery above the antecubital fossa 
using a 10 MHz linear array transducer (ultrasound sys-
tem: HP Sonos 5500), and the probe was fixed. After 2 min 
of simultaneous recording of LDF signals and the meas-
urement of brachial artery resting diameter, the pneumatic 
cuff around the forearm was inflated to suprasystolic pres-
sure for 5 min. To evoke PORH, the cuff was suddenly 
released and both the arterial diameter and the laser Dop-
pler signals were 90 min long continuously recorded. The 
baseline and postocclusive diameters of brachial artery 
were ECG gated and detected offline. FMD values were 
expressed as % change from baseline value measured at 
60 s after cuff deflation. The primary and control laser 
Doppler PORH curves were saved and later thoroughly 
evaluated (Perisoft for Windows, version 2.5.5.). Beyond 
the incorporated parameters a single observer (G.K.) dis-
solved the LDF PORH curves into resting, occlusion, 
acceleration, deceleration and at 60 s areas, and measured 
and calculated the absolute and relative time, flux, slope 
and area parameters (Fig. 1, Table 1).
Every ultrasound examination was performed by a sin-
gle trained sonographer (G.K.). In our hands, the intrao-
bserver variability (coefficient of variation) of FMD test 
was 5% and the intraclass correlation coefficient (ICC) 
required for agreement studies was 0.935.
Table 1  Definition of measured and calculated laser Doppler flow 
parameters
AH Total hyperemic area
AH/RA Total hyperemic area divided by proportional rest 
area
AUC accel Area under the curve of acceleration phase
AUC decel Area under the curve of deceleration phase
AUC1min One-minute hyperemia area after deflation
F1min One-minute absolute flux after deflation
F1min/RF One-minute absolute flux divided by rest flow
Fmeanaccel Mean flux of acceleration phase
Fmeandecel Mean flux of deceleration phase
Fmean1min One-minute mean flux after deflation
FPORHmean/RF Mean PORH flux divided by rest flow
PF Peak flow
PF–RF% Peak flow–rest flow percent change
PF/TM Peak flow/time to maximum
PU Perfusion Unit
RF Rest flow
RA One-minute rest area
Saccel Slope of acceleration phase
Sdecel Slope of deceleration phase
Tdecel Time of deceleration
TH1 Time to half before hyperemia
TH2 Time to half after hyperemia
TM Time to maximum
TR Time to recovery
Fig. 1  A representative laser Doppler flow postocclusive reactive hyperemia curve. See Table 1 for abbreviation explanations
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Determination of circulating von Willebrand factor 
levels
Circulating vWF:Ag is a marker of endothelial cell activa-
tion. Plasma levels of vWF:Ag were determined by STA 
Liatest vWF:Ag immunoturbidimetric assay using micro-
latex particles coated with polyclonal rabbit anti-human 
vWF:Ag antibodies (Diagnostica Stago, Asnieres, France). 
After mixing the reagent with plasma, the degree of agglu-
tination was proportional to the amount of vWF:Ag present 
in the plasma sample. The reference range was 50–160%. 
The blood sampling was carried out early in the morning 
after overnight fasting before the acclimatisation from the 
left arm.
Data analysis
Descriptive data of normal variables are expressed as the 
mean ± SD. Statistical analysis for comparison was carried 
out by the SPSS 22.0 software. Distributions were assessed 
by Kolmogorow–Smirnov test. Correlations between vari-
ables were determined using Pearson correlation analysis 
for normally distributed values and Spearman correlation 
analysis as non-parametric test. R values of theses correla-
tions were determined and corresponding p values < 0.05 
were considered significant. As we had only eight early RA 
patients in the follow-up pilot study, only limited statistical 
analysis could be performed in the second part of the study. 
In case of the normal distribution, differences were assessed 
by Student’s paired t test using the SPSS 22.0 software.
To define agreement of PORH parameters, the intrases-
sion variability were calculated using the identical measured 
and calculated parameters derived from primary and con-
trol laser Doppler probe. Intraclass colleration coefficients 
(ICC), coefficients of variations (CV) and Bland–Altman 
plots were applied (MedCalc 11.5.0).
Results
Simultaneous assessment of brachial artery FMD 
and laser Doppler PORH curves
After PORH test carried out in healthy individuals repre-
senting the general population (n = 46), FMD as a measure 
of macrovascular endothelial function were assessed on 
the forearm and the microcirculatory LDF PORH param-
eters detected by the primary probe were correlated with 
the reference FMD methods. LDF parameters are listed and 
explained in Table 1.
In this cohort, LDF time parameters significantly cor-
related with FMD. Both TM (p = 0.002) TH2 (p = 0.004) 
exerted significant, positive correlations with FMD. Only 
weak but statistically significant association was found 
between the FMD and the area of AUCaccel (p = 0.048). 
Neither the absolute and relative flux data, nor the most 
commonly investigated area of hyperemia and its deriva-
tives showed any correlation with FMD (Table 2).
Association of laser Doppler parameters 
with vWF:Ag levels
As described above, circulating vWF:Ag levels are indi-
cators of endothelial activation. Plasma vWF:Ag concen-
trations exerted significant negative correlation with TM 
(p = 0.009), TH1 (p = 0.014) and TH2 (p = 0.003) (Table 2). 
The absolute and relative flux and area parameters could not 
be associated with vWF:Ag concentrations.
Intrasession reproducibility of laser Doppler PORH 
parameters
Due to the significant variability of local skin circulation, 
in the healthy subject cohort, another control probe was 
placed in the near proximity of the primary detector. The 
agreement of corresponding PORH parameters derived from 
these one point probes were determined to assess their true 
clinical utility. Reproducibility values are seen in Table 2. 
Regarding LDF time parameters, TH1 seems to be the most 
reproducible. The intrasession reproducibility of TH2 is also 
acceptable, while the intrasession agreement of one point 
TM is considered to be poor. The reproducibility of all flux 
parameters was relatively poor. However, AH, AUC decel and 
AUC 1min exerted moderate reproducibility (Table 2). Thus, 
according to the ICC, CV results and the Bland–Altman 
plots the TH1 and TH2 parameters are the most stable meth-
ods in the estimation of microcirculatory endothelial func-
tion, and determination of TH2 may be the optimal method 
for a follow-up study (Fig. 2; Table 2).
Effects of adalimumab treatment on endothelial 
function in early RA
After the validation of the LDF PORH technique on 
healthy subjects, in the second part of the study, LDF was 
tested in a prospective pilot study. In 8 patients with early, 
untreated RA, adalimumab therapy successfully improved 
arthritis as it decreased CRP levels (p = 0.04) and disease 
activity (DAS28, p < 0.0001) (data not shown). Effects of 
adalimumab on endothelial function were assessed at base-
line and after 2, 4, 8 and 12 weeks of therapy. Changes 
in the most relevant LDF parameters are included in 
Table 3. Microvascular endothelial function characterized 
by TH2 times, as the most reliable indicator, significantly 
improved in comparison to baseline as early as by week 
4 (p = 0.032), and this effect was sustained until the end 
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of treatment (p = 0.013) (Table 3, Fig. 3). TH1, the most 
reproducible parameter, which otherwise poorly repre-
sents endothelial function, also improved by week 12 in 
comparison to baseline (p = 0.001). TM, a good marker 
of endothelial function with poor reproducibility did not 
show any significant changes. In this small pilot study, PF 
increased markedly, however, due to its clinical unstability, 
the elevation was not significant (Table 3).
Some of the time- and flow-dependent area parame-
ters also changed. After 8 weeks of treatment, significant 
improvement could be observed in AH (p = 0.045) and in 
AUC 1min (p = 0.019) (Table 3). However, the latter para-
maters may not reflect endothelial function as shown in our 
previous study. AUC accel, which is a moderate marker of 
endothelial function, did not show any significant improve-
ment as a consequence of poor reproducibility (Table 3).
As a positive control, brachial artery FMD and vWF:Ag 
levels were also assessed during the 12-week treatment 
follow-up period. FMD significantly improved from week 
2 compared to baseline. This improvement was sustained 
until week 12. In contrast, vWF:Ag levels did not show 
significant decreases upon anti-TNF therapy (Fig. 4).
Discussion
The assessment of ED is the earliest and most sensitive 
marker for vascular damage, also in inflammatory dis-
eases, such as RA [10, 14, 30, 31]. In the first part of 
our study, we tested PORH-provoked microcirculatory 
changes by LDF in healthy volunteers. Surprisingly, only 
the TM and TH2 parameters correlated moderately, and 
AUC accel weakly with FMD. The validity of this observa-
tion was supported by the negative correlation between 
serum levels of the endothelial activation marker vWF:Ag 
and the time parameters. In summary, the prolongation 
of PORH curves due to decreased microcirculatory flow 
indicate better endothelial function. Our results also sug-
gest, that only the time parameters, ideally TH2 may be 
used as a marker of endothelial function. Our results are 
in agreement with the early results of Carlsson et al. [32] 
indicating that PORH area is mainly prostaglandin- and 
adenosine-dependent. The NO antagonist L-NMMA pre-
treatment affected only the deceleration segment of PORH 
curve decreasing the TH2 [33], which result indirectly 
Table 2  Correlations between 
measured and calculated 
microvascular parameters, 
macrovascular endothelial 
function and endothelial 
activation
The last two columns are showing the attributes of intrasession variability of laser Doppler flow param-
eters. CV coefficient of variation, ICC intraclass correlation coefficient, NS not significant. Other abbrevia-
tions are explained in Table 1. Significant correlations are in bold italics
LDF parameter FMD(%) vWF:Ag (%) CV (%) ICC
R p R p
RF 0.050 NS 0.282 NS 52.3 0.315
PF 0.046 NS 0.197 NS 44.3 0.253
PF–RF% − 0.090 NS − 0.135 NS 57.0 0.327
AH 0.173 NS 0.106 NS 55.1 0.474
AH/RA 0.118 NS − 0.154 NS 68.2 0.262
FPORHmean/RF − 0.090 NS − 0.005 NS 54.0 0.272
TR 0.039 NS − 0.219 NS 29.3 0.804
TM 0.456 0.002 − 0.401 0.009 37.3 0.370
TH1 0.213 NS − 0.382 0.014 15.9 0.883
TH2 0.435 0.004 − 0.446 0.003 25.5 0.605
PF/TM − 0.248 NS 0.303 NS 62.2 0.253
Saccel − 0.214 NS 0.127 NS 82.7 0.153
AUC accel 0.307 0.048 0.005 NS 74.7 0.182
Fmeanaccel 0.089 NS 0.217 NS 46.3 0.272
Sdecel 0.034 NS − 0.122 NS 49.0 0.013
AUC decel 0.125 NS 0.184 NS 50.6 0.568
Fmeandecel 0.101 NS 0.147 NS 48.8 0.365
Tdecel 0.083 NS 0.057 NS 36.4 0.341
AUC 1min 0.130 NS 0.155 NS 49.8 0.409
Fmean1min 0.130 NS 0.155 NS 49.8 0.407
F1min 0.122 NS 0.184 NS 47.6 0.380
F1min/RF 0.176 NS − 0.113 NS 53.7 0.420
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supports our conclusion. Other authors observed the 
same effect of L-NMMA on the deceleration phase of 
PORH curve on the level of macrocirculation [34, 35]. 
Thus, the detailed analysis of time parameters, particularly 
the deceleration phase of PORH curves allows to detect 
endothelial function [36, 37]. Furthermore, the measure-
ment of total AH, which partly depends on the prolonga-
tion of PORH curve and TH2, may be used as a complex 
vascular function test [38]. Stiefel et al. [39] previously 
tested the excellent clinical utility of PORH studies: the 
complex vascular parameter AH showed good sensitivity 
and excellent specificity to predict coronary artery disease. 
The TH2 time prolongation seemed partly the cause of 
increased AH, and the TH2 parameter prolongation itself 
exerted good sensitivity and specificity for coronary artery 
disease. The last parameter has been above validated by 
our group as a true endothelial function marker. We also 
observed good intrasession reproducibility of time, moder-
ate of area and poor of flux parameters.
Fig. 2  The intrasession variability of most challenging variables represented with Bland–Altman plots. a, b indicate good, and c, d poor intrases-
sion agreement between LDF parameters
Table 3  Changes of laser Doppler flow parameters upon adalimumab therapy of early rheumatoid arthritis patients (n = 8)*
*See Table 1 for abbreviations and explanations. Significant changes vs baseline are in bold italics
Baseline Week 2 Week 4 Week 8 Week 12
TH1 (s) 2.34 ± 0.60 3.13 ± 0.96 (NS) 2.68 ± 0.70 (NS) 2.90 ± 1.34 (NS) 4.05 ± 0.55 (p ≤ 0.001)
TM (s) 13.42 ± 6.01 15.17 ± 7.78 (NS) 14.34 ± 4.90 (NS) 16.44 ± 7.15 (NS) 13.22 ± 4.96 (NS)
TH2 (s) 26.94 ± 8.41 34.5 ± 16.5 (NS) 34.73 ± 9.44 (p = 0.032) 40.5 ± 17.3 (p = 0.026) 32.1 ± 9.1 (p = 0.013)
AUC accel (PUxs) 445.2 ± 330.6 782.4 ± 660.7 (NS) 724.3 ± 828.3 (NS) 816.2 ± 327.5 (NS) 636.1 ± 543.4 (NS)
PF (PU) 46.4 ± 16.1 67.9 ± 40.5 (NS) 58.5 ± 41.1 (NS) 64.3 ± 22.6 (NS) 65.2 ± 40.5 (NS)
AH (PUxs) 1598 ± 892 2896 ± 2811 (NS) 2790 ± 2408 (NS) 2724 ± 1169 (p = 0.045) 3164 ± 2965 (NS)
AUC 1min (PUxs) 1468 ± 655 2522 ± 1958 (NS) 2343 ± 1917 (NS) 2461 ± 927 (p = 0.019) 2458 ± 1878 (NS)
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The detailed analysis and validation of the PORH-medi-
ated LDF technique were carried out in healthy volunteers. 
To assess its utility in a small group of rheumatic patients, 
in the second, pilot part of our study, we carried out an LDF 
and FMD pilot study in 8 patients with early untreated RA. 
To our knowledge, ours is the first pilot study to assess LDF 
parameters after PORH and not iontophoresis in early RA 
patients undergoing anti-TNF therapy. We found significant 
improvement in some LDF PORH curve parameters includ-
ing TH1, TH2, AH and AUC 1min. This was associated with 
significant improvement in FMD. Some LDF studies have 
previously been performed in chronic RA [15–25, 27, 39, 
40]. Except for one recent study that utilized PORH [22], all 
other groups used Ach and/or SNP iontophoresis to detect 
endothelium-dependent and –independent microvascular 
endothelial function, respectively [15–21, 23–25, 27, 28]. 
Most studies reported impaired skin microcirculation in RA 
as determined by LDF [15–19, 21–24, 27, 40]. Van Eijk 
et al. [28] reported preserved microcirculatory capacity 
in a cohort of early RA patients with low disease activity. 
Impaired skin microcirculation was associated with inflam-
matory activity [18] and increased CRP levels [17, 19] but 
not with low RA disease activity [28]. Others did not find 
associations between micro- or macrocirculation and inflam-
matory activity [24]. In one study, impaired Ach-induced, 
microcirculatory endothelial function could be associated 
with global cardiovascular risk [24]. Very few longitudi-
nal studies were conducted to determine the effects of anti-
rheumatic therapy including biologics on LDF parameters. 
Treatment of RA resulted in improved microcirculation in 
some studies [22, 24, 27] but not in others [17, 18]. In the 
active, established RA cohort of Galarraga et al. [18], no 
improvement of Ach or SNP iontophoresis-induced micro-
circulation could be observed upon anti-TNF therapy in the 
whole population. However, LDF parameters improved in 
responders [18]. In the only available, recent LDF PORH 
study, Ruiz-Limon et al. [22] reported improvement of skin 
microcirculation upon tocilizumab treatment of chronic RA 
Fig. 3  Changes in time to 
half after hyperemia (TH2) 
of the postocclusive reactive 
hyperemia curve representing 
microcirculation upon 12 weeks 
of adalimumab treatment in 
patients with early rheumatoid 
arthritis
Fig. 4  Changes in macrovas-
cular endothelial dysfunction 
(flow-mediated vasodilation) 
and von Willebrand factor 
antigen levels upon 12 weeks 
of adalimumab treatment in 
patients with early rheumatoid 
arthritis
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patients. Only very few studies included early RA patients 
[26, 28]. Foster et al. [26] assessed iontophoresis-induced 
LDF and FMD in 18 patients with new-onset RA. Interest-
ingly, only endothelium-independent micro- (SNP-induced) 
and macrocirculation (GTN-induced) were found to be 
impaired [26]. Similarly, as described above, Van Eijk et al. 
[28] could not demonstrate impairment of microcirculation 
in early RA patients with low CRP. Finally, only two studies 
compared micro- and macrovascular endothelial function 
in RA patients [15, 41]. Neither Arosio et al. [15] nor San-
doo et al. [41] could not demonstrate correlation between 
LDF parameters and FMD in patients with established RA. 
Thus, most LDF studies using iontophoresis demonstrated 
impaired skin microcirculation, probably associated with 
higher CRP and disease activity.
Our study may have important advantages and limita-
tions. Among the advantages… Limitations include the 
small number of patients in the second, pilot part of our 
study.
In conclusion, in our two-stage study, first we demon-
strated that the TH2 parameter of LDF PORH test may be a 
reliable and relatively stable marker of endothelial function 
in the normal population. The most commonly used area 
parameters did not correlate with macrovascular endothe-
lial function indicating they would rather complex vascular 
function parameters. We verified in a pilot study conducted 
in early RA patients that in a pathological condition, where 
reversible ED may be an important phenomenon, early, 
effective treatment may improve microcirculation and this 
can be monitored by the operator-independent laser Doppler 
technique. It remains to be determined whether LDF could 
have an additional value in cardiovascular risk stratifica-
tion. One possible limitation of our study is that we used 
single-point laser, which was sufficient to detect the com-
mon denominators of different endothelial function param-
eters. However, we do not know, whether these result could 
be extrapolated to modern laser techniques, such as LSCI. 
LSCI may, at least partly, eliminate the disadvantages of 
the one-point laser method probably by introducing more 
reproducible parameters to our experimental and clinical 
armamentarium.
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